Last Week in Medicine Half Dose DOAC for Long Term VTE Prevention, Biomarker Guided Antibiotics for Sepsis, GPT-4 Assistance for Physicians, Optimal Vasopressin Initiation for Shock, DOAC vs No AC for A fib After Intracerebral Hemorrhage, HFNC vs NIV for Respiratory Failure
5 snips
Mar 27, 2025 Join Dr. Brian Locke, an intensivist at Intermountain with a knack for statistics, as he dives into cutting-edge medical research. He discusses the effectiveness of half-dose DOACs for VTE prevention, weighing bleeding risks and treatment options. The conversation heats up around using biomarkers to guide antibiotic durations for sepsis, alongside the challenges and promises of AI, particularly GPT-4, in enhancing physician productivity. Additionally, Locke examines critical decisions around anticoagulation in atrial fibrillation and compares high-flow nasal cannula versus non-invasive ventilation for respiratory failure.
AI Snips
Chapters
Transcript
Episode notes
Consider Half-Dose DOAC
- Reduce DOAC dosage after six months for higher bleed risk patients, despite prior studies not showing reduced bleeding.
- Consider individual patient factors like bleeding events and risk before reducing.
Non-Inferiority in Question
- RENOVE trial's non-inferiority conclusion is questionable due to the low overall VTE recurrence rates.
- The trial might not have been large enough to definitively prove half-dose DOAC's non-inferiority.
Individualized DOAC Reduction
- Don't automatically reduce DOAC dosage at six months.
- Consider it for higher bleed risk patients or those experiencing bleeding events.